Signos raised $20 million to expand its glucose monitoring platform beyond diabetes into weight-loss applications. The company’s system pairs Dexcom’s over-the-counter CGM devices with an app that translates glucose readings into personalized diet and lifestyle recommendations. The funding is aimed at increasing adoption for non-diabetes use cases, positioning Signos within a growing category of CGM-enabled consumer and clinical weight management products. The company’s approach also highlights a shift toward using existing biosensing hardware to build software-driven nutrition and behavior programs. While the announcement does not detail trial designs or outcomes, the round signals continued investor appetite for platforms that can repurpose CGM data streams for metabolic and lifestyle interventions.